Skip to main content
OpenTrials
Completed

NCT Number: NCT04855916

KAFO Orthoses Versus the ABLE Exoskeleton

This randomized crossover study will compare walking with KAFO type orthoses (current standard of care) versus the ABLE Exoskeleton device, during walking in patients with spinal cord injury in a hospital setting. The ABLE Exoskeleton is a robotic exoskeleton that actively assists individuals with mobility problems to stand up, walk and sit down.

The main objective of the study is to compare the energy efficiency during gait with both devices. Secondary objectives are: compare gait kinematics, usability, user's satisfaction, physical activity and psychosocial impact. The study will also serve to evaluate the usability and safety of the ABLE Exoskeleton in clinical practice.

Subjects will complete 10 gait training sessions during a 5-week period with 1 of the 2 devices randomly selected, followed by a post-training assessment consisting of 1 session. Once the test is completed, subjects will have a 2-week rest period after which they will repeat the process with the other device for 5 weeks (followed by 1 post-training assessment session). The study will be conducted at Hospital Asepeyo Barcelona in Spain, where a total of 10 patients will be recruited.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Spinal Cord Injuries Central Nervous System Diseases Nervous System Diseases Neurologic Manifestations Paralysis Paraplegia Pathological Conditions, Signs and Symptoms Signs and Symptoms Spinal Cord Diseases Trauma, Nervous System Wounds and Injuries

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hospital Asepeyo Sant Cugat

Sant Cugat del Vallès, Barcelona, 08174, Spain

About this study

The primary objective of this study is determining the energy efficiency through gases exchange and kinematic gait analysis to compare the standard of assistance (KAFO type orthoses) and the ABLE Exoskeleton, a robotic gait assistance device, in patients with spinal cord injury (SCI) in a hospital setting.

The secondary objectives are to compare the performance of KAFO-type orthoses with that of the ABLE Exoskeleton device by:

  • Kinematic analysis of gait and spatiotemporal gait parameters.
  • Evaluation of the time and effort required to learn to use the device (usability).
  • Evaluation of the impact that physical activity has on participants after gait training.
  • Evaluation of the level of satisfaction of the participants.

In addition to these objectives, the safety of the ABLE Exoskeleton as an assistive device for gait rehabilitation in SCI patients will be evaluated throughout the study.

Participants will perform 2 training sessions per week of approximately 90 minutes duration for 5 weeks with each of the devices, completing a total of 10 sessions with KAFO type orthoses and 10 sessions with the ABLE Exoskeleton. Before starting the training period, the physical capacity of the participants will be measured. During the training period sessions, different measurements of the level of assistance, spatiotemporal gait variables and usability will be taken. Standardized clinical assessments will also be performed during sessions 5 and 10 (assessment sessions). At the end of the training period, a post-training assessment will be performed, consisting of 1 session where the physical capacity of the participants will be measured. After finishing the training period with one of the devices, participants will have a rest period of 2 weeks, after which they will change devices and repeat the whole process.

The main hypothesis of the study is that gait efficiency in patients with SCI is improved (lower energy consumption) when using the ABLE Exoskeleton device in comparison with KAFO-type orthoses. The increase in gait efficiency encourages patients to stand and walk for longer periods instead of using the wheelchair, which boosts their rehabilitation and improves their health.

Secondary hypotheses are:

  • The ABLE Exoskeleton device will improve the kinematics and spatiotemporal parameters of gait (more closely resemble the gait pattern of a healthy individual), relative to KAFO-type orthoses.
  • The ABLE Exoskeleton device will have a more positive impact on the mobility and psychosocial health of participants with SCI in the study, with respect to KAFO-type orthoses.
  • The ABLE Exoskeleton device is a safe device to use in a hospital setting as an assistive device during gait rehabilitation in SCI patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • From 18 to 70 years old
  • Chronic or subacute spinal cord injury.
  • Currently in treatment as in-patient or ambulatory in the investigational site.
  • From AIS A to AIS D with enough arm strength to withstand the bodyweight in a walking frame.
  • Previous experience walking with KAFO orthoses (must tolerate standing).
  • Ability to give informed consent

Exclusion criteria

  • WISCI II >16 without the exoskeleton.
  • 5 or more fragility fracture risk factors according to Craven et al.
  • History of fragility fractures of lower limbs in the past 2 years.
  • Deterioration > 3 points of the total International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) motor score within the last 4 weeks.
  • Spinal instability
  • Modified Ashworth scale (MAS) > 3 in lower limbs
  • Unable to tolerate 30 minutes standing without clinical symptoms of orthostatic hypotension.
  • Unable to walk 5 meters with KAFO orthoses and the support of a walking frame with wheels.
  • Psychological or cognitive issues that do not allow a participant to follow the study procedures.
  • Any neurological condition other than SCI
  • Medically unstable
  • Severe comorbidities including any condition that a physician considers to not be appropriate to complete participation in the study.
  • Ongoing skin issues
  • Height, width, weight or other anatomical constraints (such as leg length differences) incompatible with the device
  • Insufficient Range of Motion (ROM) for ABLE Exoskeleton device
  • Known pregnancy or breastfeeding

Treatment and study plan

ABLE Exoskeleton

Device

Participants will use the ABLE Exoskeleton to perform therapy activities (sit-to-stand transfers, walk, turns, balance exercises, normalized tests). Participants will perform a total of 10 training sessions of an approximate duration of 90 minutes.

KAFO Orthosis

Device

Participants will use a pair of KAFO-type passive orthosis to perform therapy activities (sit-to-stand transfers, walk, turns, balance exercises, normalized tests). Participants will perform a total of 10 training sessions of an approximate duration of 90 minutes.

Primary outcomes

  1. Measurement of gas exchange during 6 Minute Walk Test (6 MWT)

    Time frame: Session #5, Session #10. Sessions take place 2x/week over a 5 week training period.

    6 Minute Walk Test (6 MWT) measures the distance a person can walk in 6 minutes. There are different possibilities for performing this test. For this study, we will use a track of at least 10 meters, where patients walk back and forth.

  2. Measurement of gas exchange during the Timed Up and Go Test (TUG)

    Time frame: Session #5, Session #10. Sessions take place 2x/week over a 5 week training period.

    Timed Up and Go Test (TUG) measures the time it takes a person to get up from a chair, walk 3 meters, turn around and sit down again. It is a widely used test to assess balance and the risk of falls in different patient groups.

  3. Measurement of gas exchange during Graded exercise testing (GXT)

    Time frame: Change from preliminary assessment through study completion, an average of 16 weeks.

    Maximal Graded Exercise Test (GXT) is a screening tool to track an individual's fitness level. The test evaluates the participant's exercise capacity by measuring the cardiovascular response to physical activity. Through this test, the values of maximal oxygen consumption will be obtained and used to obtain metrics to assess energy efficiency during the gait.

  4. Measurement of gas exchange during 10 Meter Walk Test (10MWT)

    Time frame: Session #5, Session #10. Sessions take place 2x/week over a 5 week training period.

    The 10 Meter Walk Test (10 MWT) measures the time a person needs to walk 10 meters. The test is performed with a dynamic (flying) start with two-meter acceleration, a timed ten-meter distance and two-meter deceleration.

Secondary outcomes

  1. Measurement of the Level of Assistance to perform therapy activities.

    Time frame: Up to 5 weeks

    To measure the time required to learn to use the device under investigation, different activities (don/doff, balance, walking, advanced abilities) will be performed during the training period. The difficulty of each activity increases as they are completed.

  2. Perceived level of exertion

    Time frame: Up to 6 weeks

    For measuring impact on the perceived level of exertion, the BORG will be tested after the 6 MWT/TUG/GXT with and without the device. The BORG scale measures the subjective level of intensity in physical work on a 15-grade scale. It ranges from 6 (No exertion at all) to 20 (Maximal exertion).

  3. Fatigue Visual Analog Scale (VAS)

    Time frame: Up to 6 weeks

    The scale consists of a straight line where one end means the absence of fatigue and the other end means maximal fatigue. The patient selects a point in the line which coincides with their level of fatigue.

  4. Spinal Cord Independence Measure (SCIM) III

    Time frame: Up to 10 days before first session and up to 10 days after first session

    Spinal Cord Independence Measure (SCIM III) scale focuses on the ability to perform activities of daily living in persons with SCI. The SCIM III consists of three subscales: Self-Care, Respiratory and Sphincter Management, Mobility (room and toilet) and Mobility (indoors and outdoors, on even surface). A total score of 0 (totally dependent) to 100 (totally independent) points can be achieved.

  5. Quebec User Evaluation of Satisfaction with assistive Technology (QUEST 2.0)

    Time frame: Up to 6 weeks

    QUEST 2.0 is designed to measure the level of satisfaction and the value people attribute to assistive technologies. It does so using 12 variables which are scored on a 5 point scale in terms of perceived importance and satisfaction. While items 1-8 rate the satisfaction with the device, items 9-12 are for assessing the satisfaction with the service. If the users are not very satisfied with a feature, they are asked to provide specific feedback. The final score is the mean sum scores of all valid responses with a range of 1 (not satisfied at all) to 5 (very satisfied).

  6. Psychosocial Impact of Assistive Devices Scales (PIADS)

    Time frame: Up to 6 weeks and followup (4 weeks after study completion).

    PIADS is a 26-item (7-point Likert-Scale), self-report questionnaire designed to assess the effects of an assistive device on functional independence, well-being, and quality of life. It is divided into three subscales: Competence, adaptability and self-esteem. For each of the subscales, typically means are calculated that range from -3 (maximum negative impact) to +3 (maximum positive impact). To have only positive sum scores, the range of the individual scores are shifted to 1 to 7, meaning that the sum scores range from 1 *26 (26, maximum negative impact) to 7 *26 (182, maximum positive impact). The PIADS is a responsive measure and sensitive to important variables such as the user's clinical condition, device stigma, and functional features of the device. It has been shown to accurately reflect the self-described experiences of people who use assistive devices.

Other outcomes

  1. Gait Analysis

    Time frame: Session #5, Session #10. Sessions take place 2x/week over a 5 week training period.

    Kinematic and kinetic gait parameters will be calculated from data acquired with a motion capture system.

Sponsors and collaborators

Lead sponsor

ABLE Human Motion S.L.

Industry

Collaborators

  • Biomechanical Engineering Lab (BIOMEC) - Universitat Politècnica de Catalunya (UPC)
  • Hospital Asepeyo Barcelona
  • Institut Nacional d'Educació Física de Catalunya (INEFC)

Registry information

Official study title

ABLE Exoskeleton vs KAFO Orthosis: Comparative Study of Gait Kinematics and Energy Efficiency in Patients With Spinal Cord Injury

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Apr 22, 2021
Registry last updated
Oct 4, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.